About A public-private partnership that supports the discovery of new medicines through open access research. About SGC Partners Research Laboratories SGC-Toronto SGC-UNC SGC-Frankfurt SGC-Karolinska SGC-Neuro Governance Collaborators Open Science Equity, Diversity and Inclusion Impact Science and Resources Proteins Structure Gallery Expression Vectors Plasmids Constructs Production Protocols ChromoHub Phylogenetic Trees UbiHub Phylogenetic Trees ChemBioPort Chemical Probes Program CHEMICAL PROBES Donated chemical probes Chemical Handles Human Kinase Chemical Probe Program ANTIBODIES TARGET ENABLING PACKAGES (TEPs) TISSUE PLATFORM Open Lab Notebooks Open Chemistry Network PUBLICATIONS People Global Aled Edwards, CEO Susan McCormick, CFO Max Morgan, General Counsel and Public Policy Director SGC Toronto Cheryl Arrowsmith Dalia Barsyte-Lovejoy Takis Prinos Matthieu Schapira Levon Halabelian Rachel Harding SGC UNC Tim Willson Alison Axtman David Drewry Peter J. Brown Rafael M. Couñago SGC UCL Mat Todd SGC Karolinska Michael Sundström Opher Gileadi SGC Frankfurt Stefan Knapp Susanne Müller-Knapp Thomas Hanke Vladimir Rogov Krishnal Saxena Andreas Joerger Václav Němec Andreas Krämer Sandra Röhm SGC Neuro Edward Fon Thomas Durcan Jean-François Trempe Ziv Gan-Or Peter McPherson Carl Laflamme Roxanne Lariviere News & Outreach News & Events News from SGC Press Releases Events Blog Tweets by thesgconline Careers
A public-private partnership that supports the discovery of new medicines through open access research.
A-395 A Chemical Probe For EEDThis probe and its inactive control are available from Sigma (A-395 and A-395N) and Cayman (A-395). For any inquiries please contact proberequests@thesgc.org.group newOverview A-395 A-395N (negative control) A collaboration between Abbvie and the SGC has resulted in the discovery of A-395, the first potent and selective chemical probe for EED. The in vitro activity of A-395 includes potent binding to EED with Ki = 0.4 nM, inhibits the PRC2 complex with IC50 = 34 nM for methylation of H3K27 and greater than 100-fold selectivity over other histone methyltransferases and non-epigenetic targets. In cellular assays, A-395 inhibits the PRC2 complex (thus inhibiting the formation of H3K27me3) with IC50 = 90 nM (RD rhabdoid tumor cell line; 3 days). A closely related compound, A-395N, exhibits no activity in the biochemical and cellular assays, and is an ideal control compound for cellular studies. in vitro potency A-395 potently inhibited the formation of H3K27me3 (via antagonizing EED in the trimeric PRC2 complex (EZH2:EED:SUZ12)) with IC50 = 34 ± 2 nM (Hill Slope = 0.7) Properties A-395 A-395N (negative control) Physical and chemical properties for A-395 Molecular weight 486.2 Molecular formula C26H35FN4O2S IUPAC name 1-(5-fluoro-bicyclo[4.3.0]nona-1,3,5-trien-7-yl)-N,N-dimethyl-4-(4-(4-methylsulfonyl-piperazin-1-yl)-phenyl)-pyrrolidin-3-amine MollogP 4.425 PSA 39.69 No. of chiral centres 3 No. of rotatable bonds 5 No. of hydrogen bond acceptors 7 No. of hydrogen bond donors 0 Physical and chemical properties for A-395N Molecular weight 442.2 Molecular formula C24H34N4O2S IUPAC name 1-benzyl-N,N-dimethyl-4-(4-(4-methylsulfonyl-piperazin-1-yl)-phenyl)-pyrrolidin-3-amine MollogP 3.158 PSA 40.58 No. of chiral centres 2 No. of rotatable bonds 6 No. of hydrogen bond acceptors 7 No. of hydrogen bond donors 0 SMILES: A-395: CN(C)[C@H]1CN(C[C@@H]1c1ccc(cc1)N1CCN(CC1)S(C)(=O)=O)C1CCc2cccc(c12)F A-395N: CN(C)[C@@H]1CN(Cc2ccccc2)C[C@H]1c1ccc(cc1)N1CCN(CC1)S(C)(=O)=O InChI: A-395: InChI=1S/C26H35FN4O2S/c1-28(2)25-18-30(24-12-9-20-5-4-6-23(27)26(20)24)17-22(25)19-7-10-21(11-8-19)29-13-15-31(16-14-29)34(3,32)33/h4-8,10-11,22,24-25H,9,12-18H2,1-3H3/t22-,24?,25+/m1/s1 A-395N: InChI=1S/C24H34N4O2S/c1-25(2)24-19-26(17-20-7-5-4-6-8-20)18-23(24)21-9-11-22(12-10-21)27-13-15-28(16-14-27)31(3,29)30/h4-12,23-24H,13-19H2,1-3H3/t23-,24+/m0/s1 InChIKey: A-395: REVJNSVNICWODC-KIDMSAQOSA-N A-395N: VEABDKBNQNHHCB-BJKOFHAPSA-N Selectivity ProfileSelectivity Selectivity of A-395 against 32 methyltransferase enzymes Selectivity of a) A-395 and b) A-395N relative to epigenetic readers using a thermal shift assay A-395 inhibits the activity of the PRC2 complex in cells – high-content screening assay of RD Rhabdoid tumor cell line treated for 72 hours Co-crystal structures Please wait whilst the interactive viewer is loaded! Main features 1. Binding of A-395 to EED 2. Close-up shot of A-395 showing H-bonds. 3. A-395 superimposed with structure of PRC2 complex with Jarid2 peptide (EED site) and H3K27M in EZH2 catalytic site. EED in blue, EZH2 in gray, and SUZ12 in yellow. 4. Close-up of overlay of A-395 with Jarid2 peptide in PRC2 complex. References Yupeng He, Sujatha Selvaraju, Michael L Curtin, et al. The EED protein–protein interaction inhibitor A-395 inactivates the PRC2 complex . Nature Chem. Biol.(2017)
